South San Francisco, CA October 2, 2023 Press Release Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous…
South San Francisco, CA April 16, 2018 Genentech Press Release Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker…
South San Francisco, CA March 29, 2017 Genentech Press Release First and only approved disease-modifying therapy for primary progressive form of multiple sclerosis (PPMS) – one of the most disabling forms of multiple sclerosis (MS) An…